Share and Follow
In an important health update, a pharmaceutical company based in New Jersey has initiated a voluntary recall of thousands of bottles of a high blood pressure medication over potential cross-contamination concerns, according to the Food and Drug Administration (FDA).
The recall specifically targets over 11,100 bottles of tablets containing the combination of bisoprolol fumarate and hydrochlorothiazide, marketed under the brand name Ziac. FDA officials reported that testing of reserve samples revealed traces of ezetimibe, a medication typically prescribed for managing high cholesterol, according to an online report.
Updated:
(NewsNation) — A New Jersey drug maker has voluntarily recalled thousands of bottles of a combination high blood pressure medication over concerns the product could be cross-contaminated with another drug, the Federal Drug Administration says.
The recall covers more than 11,100 bottles of bisoprolol fumarate and hydrochlorothiazide tablets under the brand name Ziac. Testing of reserve samples showed presence of ezetimibe, a drug used for high cholesterol, FDA officials said in a report published online.
The recall level for the drug is Class III, meaning the use or exposure to the product is “not likely to cause adverse health consequences.”
Glenmark Pharmaceuticals Inc., located in Elmwood Park, is recalling the pills, which are in 2.5 mg and 6.25 mg doses.
The FDA says packages affected are:
- 30-count bottles NDC 68462-878-30
- 100-count bottle NDC-68462-878-01
- 500-count bottles NDC68462-878-05
The affected lot numbers were set to expire beginning in November 2025 through May 2026.
